Multi-Chain Chimeric Polypeptides Targeting TGF-βRII Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroinflammatory diseases, such as Alzheimer's disease and multiple sclerosis, are inadequate in reducing neuroinflammation and slowing the progression of these disorders.
Innovation Solution
Administration of a multi-chain chimeric polypeptide comprising a first chimeric polypeptide with a target-binding domain and a soluble tissue factor domain, and a second chimeric polypeptide that associate through affinity domains, specifically binding to TGF-β receptor II, to modulate neuroinflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neuroinflammatory diseases, then treatment simplicity is maintained, but effectiveness in reducing neuroinflammation is inadequate
Solution Approach 1:
The treatment agent is divided into multiple chains (first chimeric polypeptide and second chimeric polypeptide) that associate through affinity domains. Each chain contains specific functional domains (target-binding domain, soluble tissue factor domain) that perform distinct functions, allowing the complex therapeutic effect to be achieved through modular components rather than a single complex molecule
Solution Approach 2:
The invention uses chimeric polypeptides that combine domains from different sources: target-binding domains (such as antibody fragments), soluble tissue factor domains, and affinity domains. These composite structures integrate multiple functions into a single therapeutic agent that can simultaneously bind to multiple targets and modulate multiple pathways involved in neuroinflammation
2Productivity
If current treatments are used for neuroinflammatory diseases, then ease of administration is maintained, but ability to slow disease progression is insufficient
Solution Approach 1:
The chimeric polypeptide construct is designed to perform multiple functions simultaneously: binding to TGF-β receptor II to modulate immune responses, interacting with tissue factor pathways to reduce neuroinflammation, and potentially targeting multiple disease mechanisms through its various domains. This multi-functionality allows a single administration to address multiple aspects of disease progression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric polypeptide effectively reduces neuroinflammation and slows the progression of neuroinflammatory disorders by targeting TGF-β receptor II, thereby ameliorating symptoms and improving immune function.
Implementation Method 1
the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains
Implementation Method 2
the first target-binding domain and the second target-binding domain each bind specifically to a ligand of TGF-β receptor II (TGF-βRII)
Implementation Method 3
Tissue factor, normally not in contact with circulating blood, initiates the coagulation cascade upon exposure to the circulating coagulation serine protease factors
Data Source
AI summary
Provided herein are multi-chain chimeric polypeptides and use thereof in reducing neuroinflammation in a subject.